Endocyte Announces Presentations at the CAR-TCR Summit 2018
August 28, 2018 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition
August 17, 2018 08:30 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 08, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Provides Second Quarter 2018 Financial Results and Operational Update
July 31, 2018 08:01 ET
|
Endocyte, Inc.
-Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035- -Investigational new drug (IND)...
Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call
July 25, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., July 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
July 09, 2018 08:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group of...
Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year
June 26, 2018 19:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte to Join the Russell 3000® Index
June 25, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 22, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer
June 05, 2018 08:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...